Navigation Links
Cell Therapeutics Retires 7.5% Convertible Senior Notes
Date:5/1/2011

factors, technological developments, costs of developing, producing and selling CTI's product candidates, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
F: 206.272.4434
E: deramian@ctiseattle.com
www.celltherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Talecris Biotherapeutics Announces First Quarter 2011 Results
2. Nektar Therapeutics Reports First Quarter 2011 Financial Results
3. Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
4. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
5. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
6. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
7. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
8. Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment
9. Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies
10. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
11. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SPRING, Md., July 29, 2014  United Therapeutics ... announced its financial results for the second ... continued growth shows that our medicines are ... pulmonary arterial hypertension (PAH)," said Martine Rothblatt, ... Officer. "The commercial launch this quarter of ...
(Date:7/29/2014)... The first product launch from start-up ... to robotics. What sets Droidles completely apart from other ... allows them to communicate, share code with each other ... , “The invention is the system,” said Hurley Research ... life of their own, both physically and on the ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The prestigious ... of Congress was recently awarded to Juliana Hillis and ... MA, for their project, “From an Egg, Everything: America’s ... 3,000 final entries for the National History Day program ... 300 historians and educators in Washington, D.C. , The ...
(Date:7/29/2014)... White papers by Clinovo ... eClinical technologies, have been published by leading pharmaceutical publications ... long line of white papers by Clinovo to have ... Leader, Pharmaceutical Online, and OpenHealthNews. , At the request ... CTO Marc Desgrousilliers, 'The Five Essentials of Cloud ...
Breaking Biology Technology:United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3
... , SAN MARINO, Calif., Aug. 7 ... a wholly owned subsidiary called MetaCytoLytics, Inc. This company was ... Professor M. Karen Newell called "metabolic disruption technology" (MDT), which ... from glucose or from fatty acids. That process has ...
... Aug. 6 AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported ... diluted, for the three months ended June 30, 2009, compared with ... diluted, for the three months ended June 30, 2008. For the ... or $0.02 per share basic and diluted, compared with net loss ...
... ROCKVILLE, Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... and commercialization of clinical-stage product candidates for central nervous system disorders, ... 30, 2009, on Monday, August 10, 2009, before the market opens. ... that time. , , Mihael H. Polymeropoulos, M.D., ...
Cached Biology Technology:Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 2AutoImmune Inc. Reports 2009 Second Quarter Financial Results 3AutoImmune Inc. Reports 2009 Second Quarter Financial Results 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 5Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2
(Date:7/29/2014)... Achalasia is a rare disease it affects 1 in ... in the esophageal wall. While its cause remains unknown, a ... in Belgium, the University of Bonn in Germany and other ... autoimmune in origin. The study, published on 6 July in ... the mysterious disease. , When we swallow, a sphincter in ...
(Date:7/28/2014)... communities showing signs of damage from the Deepwater Horizon oil ... the Gulf of Mexico. The discovery was made by a ... State University. A paper describing this work and additional impacts ... will be published during the last week of July 2014 ... of the National Academy of Sciences . , "The footprint ...
(Date:7/28/2014)... Ariz. - Reactions among minerals and organic compounds in ... carbon cycle, they provide energy for the deep biosphere, ... However, very little is known about how minerals influence ... State University have demonstrated how a common mineral acts ... negating the need for toxic solvents or expensive reagents. ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... Two inventions created by University of Texas Medical Branch ... Texas Ignition Fund, a new program designed to spur ... One of the inventions, conceived by UTMB anesthesiology ... to deliver precise amounts of fluids to trauma and ...
... Beijing Genomics Institute announced today that BGI has added ... sequencing technologies. Two AB SOLiD Systems have been ... The AB SOLiD System generated high-throughput high quality mate-pair ... The highest throughput reached so far is 6.8 ...
... discovered that increasing age affects the way breast cancer behaves. ... likely to be diagnosed with aggressive tumours that have spread ... increasingly likely to spread, particularly if the tumours are small. ... and lymph node involvement and this study is the first ...
Cached Biology News:UTMB inventions win University of Texas System commercialization awards 2Breast cancers behave differently before and after the age of 70 2Breast cancers behave differently before and after the age of 70 3
Human IL-19 MAb (Clone 152112)...
... (1995) This book contains up ... current issues relating to the aetiology and ... have been made recently which greatly improve ... molecular neuropathology through clinical and diagnostic aspects, ...
Complement C1r [Human]...
... Beacon Designer designs oligos for SYBR Green, ... NASBA and FRET assays. Highly specific primers ... by automatically interpreting BLAST search results. Primer ... structures identified by connecting to the Mfold ...
Biology Products: